Navigation Links
SyntheMed To Present at the AdvaMed 2008 MedTech Conference
Date:9/18/2008

ISELIN, N.J., Sept. 18 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion, drug delivery products and other surgical implants, announced today that it was selected to present at the AdvaMed 2008 MedTech conference being held in Washington, D.C. on September 21-24, 2008. Robert P. Hickey, President and CEO of SyntheMed, is scheduled to present on Wednesday, September 24, at 9:30 a.m. Mr. Hickey's PowerPoint presentation may be viewed at http://www.synthemed.com for thirty days after the presentation.

The purpose of the AdvaMed 2008 MedTech conference is to provide the opportunity for companies in the life sciences sector to present to an elite audience of potential investors, strategic partners and business collaborators. The selection of presenting companies is based on such criteria as: stage of product development, partnering opportunities, potential for licensing technology, intellectual property, timing of next capital raise, and overall appeal to the audience.

About AdvaMed

AdvaMed is the world's largest medical technology trade association representing over 1,600 medical technology innovators, manufacturers of medical devices, diagnostic products and medical information systems.

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion, drug delivery products, and other surgical implants. The company is primarily focused on the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technology.

Statements in this press release that are not statements of historical fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the company's efforts to obtain and maintain required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
2. SyntheMed Files Universal Shelf Registration
3. SyntheMed to Present at the Acumen BioFin Conference
4. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
5. eResearchTechnology, Inc. to Present at the UBS Global Life Sciences Conference on September 23rd, 2008
6. Caliper Life Sciences to Present at UBS Global Life Sciences Conference
7. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Conference
9. BioVex to Present at the UBS Global Life Sciences Conference
10. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
11. CryoLife to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... May 22, 2017 , ... Cancer diagnostics and pathology ... B2 at the Association for Pathology Informatics Annual Summit at the ... demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will present research it ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph ... at the Prince Of Wales Private Hospital. The procedure was performed on a ... patient failed conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic disc ...
(Date:5/18/2017)... ... May 17, 2017 , ... Cognition ... and commercialization, has just released version 9.0 of the Cognition Cockpit platform. , ... of Cockpit,” says David Cronin, CEO of Cognition. “We’re thrilled to finally be ...
(Date:5/18/2017)... ... May 18, 2017 , ... When James Sherley, was notified earlier this year that his company ... the Year 2017 by The Silicon Review , he was not surprised as others ... Asymmetrex’s value, but this recognition by Silicon Valley was particularly meaningful. Our selection ...
Breaking Biology Technology:
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):